The effects of lisuride and some other dopaminergic agonists on receptor binding in human brain.
The effect of lisuride, bromocriptine, CQ 32-084 and CU 32-085 on the specific binding of radiolabelled spiperone to homogenates of human putamen taken post-mortem has been investigated. In addition, the binding of 3H-lisuride to such preparations has been studied. Lisuride is found to inhibit spiperone binding to the dopamine receptor at very low concentrations and to bind to the beta-adrenergic receptor at somewhat higher levels. Lisuride binding to the dopamine receptor was found to be antagonist-like. A measure of the in vivo effect of lisuride was obtained from investigations of brain tissue taken from a patient treated with the drug before death.
D001921:Brain / Q000187:drug effects / Q000378:metabolism*; D001971:Bromocriptine / Q000494:pharmacology*; D004873:Ergolines / Q000494:pharmacology*; D006801:Humans; D007700:Kinetics; D008090:Lisuride / Q000494:pharmacology*; D011954:Receptors, Dopamine / Q000187:drug effects / Q000378:metabolism*; D013134:Spiperone / Q000378:metabolism
D004873:Ergolines; D011954:Receptors, Dopamine; C031648:etisulergine; D001971:Bromocriptine; D013134:Spiperone; D008090:Lisuride; C031649:mesulergine